These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 17624049)

  • 21. Lenalidomide and venous thrombosis in multiple myeloma.
    Knight R; DeLap RJ; Zeldis JB
    N Engl J Med; 2006 May; 354(19):2079-80. PubMed ID: 16687729
    [No Abstract]   [Full Text] [Related]  

  • 22. Fatal amebic colitis after high-dose dexamethasone therapy for newly diagnosed multiple myeloma.
    Kobayashi CI; Yamamoto G; Hayashi A; Ota S; Imai Y; Fukayama M; Kurokawa M
    Ann Hematol; 2011 Feb; 90(2):225-6. PubMed ID: 20467744
    [No Abstract]   [Full Text] [Related]  

  • 23. Trials investigate first-line thalidomide in multiple myeloma.
    Owen OG
    Lancet Oncol; 2005 Jan; 6(1):6. PubMed ID: 15672486
    [No Abstract]   [Full Text] [Related]  

  • 24. Thalidomide in the treatment of multiple myeloma.
    Kastritis E; Dimopoulos MA
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):681-99. PubMed ID: 18070713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rapid complete remission in multiple myeloma with bortezomib/thalidomide/dexamethasone combination therapy following development of tumor lysis syndrome.
    Chim CS
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):181-2. PubMed ID: 17846773
    [No Abstract]   [Full Text] [Related]  

  • 26. [Guideline for the appropriate use of thalidomide in the treatment of multiple myeloma].
    Rinsho Ketsueki; 2005 Jan; 46(1):22-42. PubMed ID: 16724412
    [No Abstract]   [Full Text] [Related]  

  • 27. Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy?
    Mateos MV; García-Sanz R; Colado E; Olazábal J; San-Miguel J
    Br J Haematol; 2008 Feb; 140(3):324-6. PubMed ID: 18067473
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thalidomide-dexamethasone versus interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study.
    Offidani M; Corvatta L; Polloni C; Piersantelli MN; Gentili S; Galieni P; Visani G; Alesiani F; Catarini M; Brunori M; Samori A; Burattini M; Centurioni R; Ferranti M; Giuliodori L; Candela M; Mele A; Marconi M; Leoni P
    Br J Haematol; 2009 Mar; 144(5):653-9. PubMed ID: 19036082
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Leukocytoclastic vasculitis due to thalidomide in multiple myeloma.
    Yildirim ND; Ayer M; Küçükkaya RD; Alpay N; Mete O; Yenerel MN; Yavuz AS; Nalçaci M
    Jpn J Clin Oncol; 2007 Sep; 37(9):704-7. PubMed ID: 17709605
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumour lysis syndrome in myeloma.
    Sonneveld P
    Neth J Med; 2002 Jul; 60(6):263. PubMed ID: 12365472
    [No Abstract]   [Full Text] [Related]  

  • 31. Lenalidomide in combination with dexamethasone for the treatment of multiple myeloma after one prior therapy.
    Hazarika M; Rock E; Williams G; Dagher R; Sridhara R; Booth B; Farrell A; Justice R; Pazdur R
    Oncologist; 2008 Oct; 13(10):1120-7. PubMed ID: 18922829
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neutrophilic dermatosis complicating lenalidomide therapy.
    Thieu KP; Rosenbach M; Xu X; Kist JM
    J Am Acad Dermatol; 2009 Oct; 61(4):709-10. PubMed ID: 19577327
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lenalidomide and its role in the management of multiple myeloma.
    Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
    Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thalidomide-associated thrombocytopenia.
    Duyvendak M; Naunton M; Kingma BJ; Brouwers JR
    Ann Pharmacother; 2005 Nov; 39(11):1936-9. PubMed ID: 16219892
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.
    Lonial S; Richardson PG; San Miguel J; Sonneveld P; Schuster MW; Bladé J; Cavenagh J; Rajkumar SV; Jakubowiak AJ; Esseltine DL; Anderson KC; Harousseau JL
    Br J Haematol; 2008 Oct; 143(2):222-9. PubMed ID: 18713253
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of thalidomide in previously untreated patients with multiple myeloma.
    Musto P; D'Auria F; Pietrantuono G; Bringhen S; Morabito F; Di Raimondo F; Pozzi S; Sacchi S; Boccadoro M; Palumbo A; ;
    Expert Rev Anticancer Ther; 2008 Oct; 8(10):1569-80. PubMed ID: 18925849
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Should we screen patients for inherited thrombophilia before starting thalidomide?
    Otrock ZK; Mahfouz RA; El-Hajj II; Harb MI; Sawaya RA
    Am J Clin Oncol; 2006 Feb; 29(1):100-1. PubMed ID: 16462512
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
    Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
    Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Refractory multiple myeloma treated with homoharringtonine: report of two cases.
    Yang X; Yang C; Shao K; Ye X; Meng H; Zhou Y; Qian W
    Ann Hematol; 2007 Dec; 86(12):919-21. PubMed ID: 17641891
    [No Abstract]   [Full Text] [Related]  

  • 40. Deep vein thrombosis occurring on treatment of patients receiving thalidomide with erythropoietin.
    Chennuru S; Baumann MA
    Intern Med J; 2007 Jul; 37(7):506-7. PubMed ID: 17547733
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.